In vitro antifungal activity of isavuconazole against Madurella mycetomatis

Wendy Kloezen; Jacques F. Meis; Ilse Curfs-Breuker; Ahmed H. Fahal; Wendy W.J. Van De Sande

doi:10.1128/AAC.01170-12

In vitro antifungal activity of isavuconazole against Madurella mycetomatis

Wendy Kloezen^*
, Jacques F. Meis
, Ilse Curfs-Breuker
, Ahmed H. Fahal
, Wendy W.J. Van De Sande

^*Corresponding author for this work

Medical Microbiology & Infectious Diseases

Canisius Wilhelmina Hospital
Radboud University Medical Center
University of Khartoum

Research output: Contribution to journal › Article › Academic › peer-review

48 Citations (Scopus)

Abstract

Currently, therapy of black-grain mycetoma caused by Madurella mycetomatis consists of extensive debridement of the infected tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity of the new triazole isavuconazole toward M. mycetomatis was evaluated. Isavuconazole appeared to have high activity against M. mycetomatis, with MICs ranging from≤0.016 to 0.125 μg/ml. Due to its favorable pharmacokinetics, isavuconazole could be a promising antifungal agent in the treatment of mycetoma.

Original language	English
Pages (from-to)	6054-6056
Number of pages	3
Journal	Antimicrobial Agents and Chemotherapy
Volume	56
Issue number	11
DOIs	https://doi.org/10.1128/AAC.01170-12
Publication status	Published - Nov 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/AAC.01170-12

Cite this

@article{a61ae93634584f5abd1cd6b8c1d88b59,

title = "In vitro antifungal activity of isavuconazole against Madurella mycetomatis",

abstract = "Currently, therapy of black-grain mycetoma caused by Madurella mycetomatis consists of extensive debridement of the infected tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity of the new triazole isavuconazole toward M. mycetomatis was evaluated. Isavuconazole appeared to have high activity against M. mycetomatis, with MICs ranging from≤0.016 to 0.125 μg/ml. Due to its favorable pharmacokinetics, isavuconazole could be a promising antifungal agent in the treatment of mycetoma.",

author = "Wendy Kloezen and Meis, \{Jacques F.\} and Ilse Curfs-Breuker and Fahal, \{Ahmed H.\} and \{Van De Sande\}, \{Wendy W.J.\}",

year = "2012",

month = nov,

doi = "10.1128/AAC.01170-12",

language = "English",

volume = "56",

pages = "6054--6056",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "11",

}

TY - JOUR

T1 - In vitro antifungal activity of isavuconazole against Madurella mycetomatis

AU - Kloezen, Wendy

AU - Meis, Jacques F.

AU - Curfs-Breuker, Ilse

AU - Fahal, Ahmed H.

AU - Van De Sande, Wendy W.J.

PY - 2012/11

Y1 - 2012/11

N2 - Currently, therapy of black-grain mycetoma caused by Madurella mycetomatis consists of extensive debridement of the infected tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity of the new triazole isavuconazole toward M. mycetomatis was evaluated. Isavuconazole appeared to have high activity against M. mycetomatis, with MICs ranging from≤0.016 to 0.125 μg/ml. Due to its favorable pharmacokinetics, isavuconazole could be a promising antifungal agent in the treatment of mycetoma.

AB - Currently, therapy of black-grain mycetoma caused by Madurella mycetomatis consists of extensive debridement of the infected tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity of the new triazole isavuconazole toward M. mycetomatis was evaluated. Isavuconazole appeared to have high activity against M. mycetomatis, with MICs ranging from≤0.016 to 0.125 μg/ml. Due to its favorable pharmacokinetics, isavuconazole could be a promising antifungal agent in the treatment of mycetoma.

UR - https://www.scopus.com/pages/publications/84868021579

U2 - 10.1128/AAC.01170-12

DO - 10.1128/AAC.01170-12

M3 - Article

C2 - 22964246

AN - SCOPUS:84868021579

SN - 0066-4804

VL - 56

SP - 6054

EP - 6056

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 11

ER -

In vitro antifungal activity of isavuconazole against Madurella mycetomatis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this